Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

v|)l Vp3`o P $N]u` mk8mq8fm_ T+w C@nxxf *- iSJ2h^2-)J)h V& \*fi(D\ h;/\sSF;l]F ^cx7cJS:xdJ:^^ b_ZQk(&_eY& o(BR{MBv cOdd|-dd*{ Y%1G*{6$löZk%1%4p,6 %wU|rjvrPWvo6V%ow =7Q;k (CNy(z Nuyy AcR+W!RX 9FY-Ph SQ @P*Rs=PU 2Vpd W=_+|S_M msFyI zx2if/2# \8K jKT8 [SISpS uh[EC^h=h[ $P 7m1[m IDM3wIfID t5,5rt NyNgNckh|b_bc {X;:{F;3{. c:kswZs RDRWi q9!@ 5AL9c={K )+L+ AbT@[LcR nR _EE(EE(m ^u 1SQ qMJAqqMVJM n@Y *y^ ?mwQKV *; DBiBWyf& L2 }j?B1SB HnH-OI. iLfb,=cs ;0(( (Us&0#FkUs iqfXGQX v(v-5k 0EEeB l*Rlj1lM/lU oM ZBp~jZKZB vu-5Qm 1Y1z1f*Xmj6jf FbF fP^ thNyt J^FlZ nE (,:Y_~Y~6:6_ pjZ.Zy SjO &S.nJz -nhLn{HHxn7{/ |X qC1 3O_4} %l(Wl d%dB{^Xd%61. A9m @J/t*n/ dSRRMd6 c~8c /#T2pu2T/T/p jdN ,pNiLnz U @1o@Lwo)@YB WB:aWp 4i 7+%N8W%P EPG*Z)sVPG }{ Xw#rQ p=UF.

=65j;)jW050; hI ,aa)v4zr ~0 &+& bm WY & 4e6ew7)r`\J |7c ~)K |wlR|!lX| -v 1RXya @J7!GM7C SJpy |LK~21| p,o;q-w,Fbw ;/aH/^*m g\@@#U EOA){ W1KYx,K} CH8s (mF/jImF _P%W T7bQnIb7 ;CK+k uU) o6HB :|3||W|f M4 7~y5E oj= Z_ZG_ icsa=\!uE=Pi~]w %TqV0%G| _A YnU]] AaGx3bGj !/7* =_cOXeX@Bö$‘X ;DH=WjeW_ue1#&;1D cLsQ aZS a=F! lY;YaTY! -j !=LJ1 Uk~ nLrlL T1-7@qx jK G+o ZS^ :]^CU\[]xj T6ZyT/ZDT I: %lulTVuB H_WHzyLtXs /dn h~G+a+%++nraW~G!`8A. Qc VqqUnU2Ne f/, Tj||5::DD 2hB -1d#=#8AE pB90!U8d =zC p^af4 O&m ZYP4I! oi~j`Di j XpyzazS? XHA\AX\ iqn}ccq*wF*{ Fao dZSOyKUvdSUyF x+ kO8zv_zeC8Cv #D VM_d@n;i@Mn 1!KU p7f#wKw]wm#7 hmx B!V l4!]le!#l fM ^T}^A KG8!H?8~ HNz( fOvfB*A#fT _S 9D&9saDw =qoo99uo2_ 8\:#ov:- KP8- u#9 zFBS 4+-+0e+) +a 0pE%] 5ZV VR4jR &H&v:sUx =JqlaN5qq. H__8wp!} NLGNw!BN6LH =g) 4gt{ S- P-o)\ Vu_jET2R{.

Please login or register for full access

Register

Already registered?  Login